Neurodegeneration mediated by the mTOR pathway is ameliorated with rapamycin treatment, indicating that rapamycin may serve as a targeted drug treatment for NSF-related DEE. The gene discussed is MTOR; the disease is developmental and epileptic encephalopathy.